China Biotech Services Holdings Limited released its latest GEM Company Information Sheet (data as of 3 August 2026), highlighting ownership, capital structure and business scope updates.

Shareholding structure • Genius Lead Limited owns 54.27% of issued shares. • Genius Earn Limited, the parent of Genius Lead, is also deemed interested in the same 54.27%. • Chairman Liu Xiaolin directly holds 4.69 million shares and, through 100% ownership of Genius Earn, controls a total of 54.75% of the company’s 975.73 million issued shares.

Capital and listing particulars • 975.73 million ordinary shares are in issue, each with par value of HK$0.10; board lot size is 5,000 shares. • The company was incorporated in the Cayman Islands, continued in Bermuda, and has been listed on GEM since 17 June 2004.

Convertible bond liabilities • US$6.00 million 2024 Convertible Bonds: conversion price adjusted to HK$1.11 per share, allowing up to 42.43 million conversion shares; maturity on 27 December 2026. • US$35.00 million 2026 Convertible Bonds: conversion price HK$0.66 per share, allowing up to 412.58 million conversion shares; maturity on 20 February 2030. • The full principal of both tranches—US$41.00 million—remains outstanding.

Business segments 1) Medical laboratory testing and health-check services in Hong Kong. 2) Tumor immune cell therapy and health management services in mainland China. 3) Sale and distribution of health-related and pharmaceutical products in mainland China and Hong Kong. 4) Boron neutron capture therapy services in mainland China. 5) Insurance brokerage services in Hong Kong.

Corporate governance The board comprises three executive directors (including Chairman Liu Xiaolin) and three independent non-executive directors. The company employs RSM Hong Kong as auditor and maintains its Hong Kong headquarters at Sino Plaza, Causeway Bay.

The directors collectively accept full responsibility for the accuracy and completeness of the disclosed information.